IMMUNEERING CORP - CLASS A (IMRX)
US45254E1073 - Common Stock
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options
/PRNewswire/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative...
Immuneering Launches Pancreatic Cancer Advisory Board
Immuneering Launches Pancreatic Cancer Advisory Board
Immuneering Launches Pancreatic Cancer Advisory Board ...
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025...
Stay updated with the stocks that are on the move in today's pre-market session.
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma ...
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
Immuneering to Present at the Piper Sandler 36th Annual Healthcare Conference...
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates...
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in...
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates...
Why is Immuneering (IMRX) Stock Up 24% Today?
Up nearly 25% in today's session on a fast track designation for a key pancreatic cancer drug candidate, IMRX stock is coming into focus.
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer ...
Immuneering to Present at the Jefferies Global Healthcare Conference
Immuneering to Present at the Jefferies Global Healthcare Conference
Immuneering to Present at the Jefferies Global Healthcare Conference...
Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment
/PRNewswire/ -- USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect...
IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024
IMRX stock results show that Immuneering missed analyst estimates for earnings per share the first quarter of 2024.
IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immuneering (NASDAQ:IMRX) just reported results for the first quarter of 2024.I...
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates...
Immuneering Recognizes Melanoma Awareness Month
Immuneering Recognizes Melanoma Awareness Month
Immuneering Recognizes Melanoma Awareness Month...